RT Journal Article SR Electronic T1 Newer oral and noninsulin therapies to treat type 2 diabetes mellitus JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP S18 OP S26 DO 10.3949/ccjm.83.s1.04 VO 83 IS 5 suppl 1 A1 Hermayer, Kathie L. A1 Dake, Andrew YR 2016 UL http://www.ccjm.org/content/83/5_suppl_1/S18.abstract AB The pathophysiology of type 2 diabetes mellitus involves several biologic mechanisms and no single medication addresses them all. Most patients require more than one medication to adequately treat their diabetes, needing drugs with unique and complementary mechanisms of action to address and balance insulin and glucagon levels. In the past decade, several therapeutic drug classes have been developed for type 2 diabetes mellitus. Each provides therapeutic options with novel mechanisms of action to help clinicians achieve the goal of glucose homeostasis while controlling adverse events, especially reducing the risk of hypoglycemia.